Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T in advanced solid tumors
NCT03182816Phase 2Unknown
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Antibody Conjugates, CAR-T Cells, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of autologous EGFR-specific CAR-T cells expressing anti-PD-1/CTLA-4 antibodies in solid tumor. Status: unknown.
02
Drugs
autologous EGFR-specific CAR-T cells expressing anti-PD-1/CTLA-4 antibodies
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03182816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182816.